Lansoprazole(Synonyms: 兰索拉唑; AG-1749)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Lansoprazole (Synonyms: 兰索拉唑; AG-1749) 纯度: ≥98.0%

Lansoprazole (AG 1749) 是质子泵抑制剂，能抑制胃酸生成。Lansoprazole (AG 1749) 是中性鞘磷脂酶 (N-SMase) 的抑制剂(外泌体抑制剂)。

Lansoprazole(Synonyms: 兰索拉唑; AG-1749)

Lansoprazole Chemical Structure

CAS No. : 103577-45-3

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
500 mg ￥500 In-stock
1 g ￥660 In-stock
5 g ￥2860 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Lansoprazole 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Immunology/Inflammation Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Metabolism/Protease Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Antibacterial Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Exosomes Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Lipid Metabolism Compound Library
  • Rare Diseases Drug Library

生物活性

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

体外研究
(In Vitro)

Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC50 of 0.76 μM)[4].
Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level[3].
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss albino mice (20–25 g) of either sex[3].
Dosage: 20 mg/kg, 40 mg/kg.
Administration: PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result: Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.

Clinical Trial

分子量

369.36

Formula

C16H14F3N3O2S
CAS 号

103577-45-3
中文名称

兰索拉唑
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (270.74 mM; Need ultrasonic)

H2O : 0.1 mg/mL (0.27 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7074 mL 13.5369 mL 27.0739 mL
5 mM 0.5415 mL 2.7074 mL 5.4148 mL
10 mM 0.2707 mL 1.3537 mL 2.7074 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.77 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.77 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.

    [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

    [3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487.

    [4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51.

    [5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务